Fotios Loupakis

Summary

Publications

  1. doi FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    F Loupakis
    Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Via Roma 67, 56126 Pisa, Italy Electronic address
    Eur J Cancer 50:57-63. 2014
  2. pmc Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab
    Fotios Loupakis
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States of America
    PLoS ONE 8:e66774. 2013
  3. pmc Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
    F Loupakis
    Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Via Roma 57, 56126 Pisa, Italy
    Br J Cancer 108:2549-56. 2013
  4. doi Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies
    Fotios Loupakis
    Unit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy
    Cancer 118:1523-32. 2012
  5. doi Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer
    Fotios Loupakis
    University of Pisa, Department of Oncology, Transplants and New Technologies in Medicine, Pisa, Italy
    Expert Opin Biol Ther 11:519-31. 2011
  6. doi PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
    Fotios Loupakis
    Department of Oncology, Azienda USL 6, Istituto Toscano Tumori, Livorno, Italy
    J Clin Oncol 27:2622-9. 2009
  7. doi Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
    Fotios Loupakis
    Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori and Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Via Roma, 67, 56126, Pisa, Italy
    Cancer Chemother Pharmacol 66:559-66. 2010
  8. ncbi Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients
    Fotios Loupakis
    Division of Medical Oncology, Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Italy
    Curr Cancer Drug Targets 10:37-45. 2010
  9. pmc Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
    Fotios Loupakis
    U, O, Oncologia Medica 2 Universitaria, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori and Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina, Universita di Pisa, Italy
    BMC Cancer 11:247. 2011
  10. pmc Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    BMC Cancer 9:303. 2009

Collaborators

Detail Information

Publications31

  1. doi FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    F Loupakis
    Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Via Roma 67, 56126 Pisa, Italy Electronic address
    Eur J Cancer 50:57-63. 2014
    ..The aim of this work was to prospectively validate our retrospective finding...
  2. pmc Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab
    Fotios Loupakis
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States of America
    PLoS ONE 8:e66774. 2013
    ..The primary objective of this work was to prospectively validate that retrospective finding. A confirmatory analysis of other SNPs of VEGF/VEGFR pathway genes was included...
  3. pmc Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
    F Loupakis
    Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Via Roma 57, 56126 Pisa, Italy
    Br J Cancer 108:2549-56. 2013
    ..FOLFOXIRI plus bevacizumab produced promising early clinical results and is under investigation in several randomised trials, although no data are currently available on its effects on response of CLMs and on liver toxicities...
  4. doi Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies
    Fotios Loupakis
    Unit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy
    Cancer 118:1523-32. 2012
    ..Antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies (MoAbs) are indicated for the treatment of metastatic colorectal cancer patients, but some scientific issues concerning their efficacy are currently unsolved...
  5. doi Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer
    Fotios Loupakis
    University of Pisa, Department of Oncology, Transplants and New Technologies in Medicine, Pisa, Italy
    Expert Opin Biol Ther 11:519-31. 2011
    ..Nowadays, treatment options range from monotherapies with biologics or traditional chemotherapeutic agents to intensive combinations of chemotherapy plus targeted drugs...
  6. doi PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
    Fotios Loupakis
    Department of Oncology, Azienda USL 6, Istituto Toscano Tumori, Livorno, Italy
    J Clin Oncol 27:2622-9. 2009
    ..This retrospective study investigated the role of PTEN loss, AKT phosphorylation, and KRAS mutations on the activity of cetuximab plus irinotecan in patients with metastatic colorectal cancer (mCRC)...
  7. doi Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
    Fotios Loupakis
    Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori and Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Via Roma, 67, 56126, Pisa, Italy
    Cancer Chemother Pharmacol 66:559-66. 2010
    ..We aimed to evaluate the activity and the safety profile of sequential chemotherapy with 5-FU-based doublets with C, Ir and D in the first-line treatment of AGC...
  8. ncbi Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients
    Fotios Loupakis
    Division of Medical Oncology, Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Italy
    Curr Cancer Drug Targets 10:37-45. 2010
    ..This review aims at resuming the state-of-the-art about the role of VEGF pathway inhibitors in the treatment of mCRC and at focusing on the present knowledge about candidate biomarkers as predictors of activity and toxicity...
  9. pmc Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
    Fotios Loupakis
    U, O, Oncologia Medica 2 Universitaria, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori and Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina, Universita di Pisa, Italy
    BMC Cancer 11:247. 2011
    ..Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identified yet. Specific VEGF polymorphisms may affect gene transcription and therefore indirectly influence the efficacy of bevacizumab...
  10. pmc Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    BMC Cancer 9:303. 2009
    ..Based on these findings we investigated the correlation between both FISH and CISH EGFR GCN and clinical outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab...
  11. doi Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen
    Lorenzo Fornaro
    U O Oncologia Medica 2 Universitaria, Polo Oncologico Area Vasta Nord Ovest, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy
    Clin Colorectal Cancer 11:71-6. 2012
    ..We evaluated the outcome of second-line treatments among 196 patients treated with first-line FOLFOXIRI in three consecutive trials conducted by the Gruppo Oncologico Nord Ovest group...
  12. doi Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases
    Gianluca Masi
    Unità Operativa Oncologia Medica, Azienda USL 6, Istituto Toscano Tumori, Livorno, Italy
    Ann Surg 249:420-5. 2009
    ..The objective of this study was to evaluate the long-term outcome of resected patients and the impact of FOLFOXIRI on perioperative morbidities, mortality, and chemotherapy induced hepatotoxicity...
  13. doi Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis
    Gianluca Masi
    U O Oncologia Medica 2 Universitaria Polo Oncologico, Azienda Ospedaliero Universitaria Pisana, Via Roma, 67 56126 Pisa, Italy
    J Natl Cancer Inst 103:21-30. 2011
    ....
  14. doi Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status
    Lorenzo Fornaro
    U O Oncologia Medica 2 Universitaria, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
    Crit Rev Oncol Hematol 78:243-51. 2011
    ..Scarce data are available about safety and efficacy of cetuximab in elderly metastatic colorectal cancer (mCRC) patients...
  15. doi Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine
    Gianluca Masi
    UO Oncologia Medica 2 Universitaria, Ospedale Santa Chiara, Pisa, Italy
    Nat Rev Clin Oncol 6:670-4. 2009
    ..She initially received a long-acting somatostatin analog (octreotide) and chemotherapy with cisplatin and etoposide, which was ineffective...
  16. doi Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
    Gianluca Masi
    Unità Operativa Oncologia Medica Universitaria, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy
    Lancet Oncol 11:845-52. 2010
    ..We therefore assessed the safety and activity of the combination of FOLFOXIRI plus bevacizumab in patients with colorectal cancer...
  17. doi PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients
    Bruno Vincenzi
    Department of Oncology, University Campus Bio Medico, Rome, Italy
    J Cell Physiol 227:927-33. 2012
    ..This study represents the first evidence of a possible correlation between PML protein expression and outcome of metastatic colorectal cancer patients treated with oxaliplatin/fluoropyrimidine-based first line therapy...
  18. doi High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
    Daniele Santini
    Department of Oncology, University Campus Bio Medico, Rome, Italy
    Oncologist 13:1270-5. 2008
    ..Nevertheless, most experiences were conducted on samples from primaries. The aim of this study was to evaluate the grade of concordance in terms of KRAS status between primaries and related metastases...
  19. doi Palliative treatment of unresectable metastatic colorectal cancer
    Lorenzo Fornaro
    Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori, Medical Oncology Unit 2, Italy
    Expert Opin Pharmacother 11:63-77. 2010
    ....
  20. ncbi Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer
    Gianluca Masi
    Department of Oncology, Division of Medical Oncology, Presidio Ospedaliero, Viale Alfieri 36, Livorno, 57124, Italy
    Ann Surg Oncol 13:58-65. 2006
    ..The prognosis of unresectable metastatic colorectal cancer might be improved if a radical surgical resection of metastases could be performed after a response to chemotherapy...
  21. doi Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?
    Fotios Loupakis
    Division of Medical Oncology, Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Pisa, Italy
    Nat Rev Clin Oncol 7:190-1. 2010
    ....
  22. doi Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer
    Gianluca Masi
    Department of Oncology, Azienda USL 6 of Livorno, Istituto Toscano Tumori, Livorno, Italy
    Clin Colorectal Cancer 7:7-14. 2008
    ....
  23. pmc Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
    Fotios Loupakis
    UO Oncologia Medica 2 Universitaria, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
    J Exp Clin Cancer Res 29:58. 2010
    ..Although the addition of bevacizumab to 1st line chemotherapy provides a significant survival benefit for advanced colorectal cancer, the magnitudes of both advantages and toxicities have not been extensively investigated...
  24. ncbi EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach
    Fotios Loupakis
    Azienda USL 6 Livorno, Division of Medical Oncology, Viale Alfieri 36, 57100 Livorno, Italy
    Pharmacogenomics 9:55-69. 2008
    ..Moving from clinical data suggesting that there could be a subpopulation of CRC patients that are more liable to benefit from anti-EGFR monoclonal antibodies, here we review major studies on determinants of outcome in this field...
  25. doi First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?
    Fotios Loupakis
    Department of Oncology, Azienda USL 6, Istituto Toscano Tumori, Livorno, Italy
    Curr Opin Oncol 20:459-65. 2008
    ..This review focuses on what should be considered to define the optimal approach to each patient, in particular with regard to the intensiveness of first-line chemotherapy...
  26. pmc Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
    Giacomo Allegrini
    Division of Medical Oncology, Pontedera, Pisa, Italy
    Angiogenesis 15:275-86. 2012
    ..To evaluate UFT and cyclophosphamide (CTX) based metronomic chemotherapy plus celecoxib (CXB) for the treatment of patients with heavily pre-treated advanced gastrointestinal malignancies...
  27. pmc Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer
    Fotios Loupakis
    Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana and Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Italy
    Ther Adv Med Oncol 1:167-81. 2009
    ....
  28. pmc Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States
    Takeru Wakatsuki
    Corresponding Author Heinz Josef Lenz, Sharon A Carpenter Laboratory, Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, 1441 Eastlake Avenue, Los Angeles, CA 90033
    Mol Cancer Ther 12:2261-72. 2013
    ..These findings suggest that the estrogen pathway may play a prognostic role in patients with gastric cancer but this may be dependent on the regional differences both in physiology and genetic alterations of gastric cancer...
  29. doi The possible role of chemotherapy in antiangiogenic drug resistance
    Guido Bocci
    Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma 55, Pisa 56126, Italy
    Med Hypotheses 78:646-8. 2012
    ..In conclusion, the consequences of our hypothesis could be promptly translated into the preclinical studies and verified in clinical trials, involving cancer patients resistant to chemotherapy plus antiangiogenic drug schedules...
  30. doi Liquid biopsy: monitoring cancer-genetics in the blood
    Emily Crowley
    Department of Oncology, University of Turin, Institute for Cancer Research and Treatment, Strada Provinciale 142 km 3 95, 10060 Candiolo, Turin, Italy
    Nat Rev Clin Oncol 10:472-84. 2013
    ....
  31. doi A perspective on the current management of advanced colorectal cancer
    Mariaelena Casagrande
    Department of Oncology, University and General Hospital, Udine, Italy
    Future Oncol 9:1687-91. 2013
    ..Briefly summarizing all the news coming from this moving landscape, this article focuses on the results of the major randomized Phase III trials presented at the meeting. ..